Oncolytics Biotech Stock Forecast
NASDAQ: ONCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 0.5806 +4.24%
ONCY analyst consensus
Consensus (6 analysts)
buy
Avg. price target
$4.15+645.06%
- Strong buy 3
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Oncolytics Biotech (2026-10-09), 5 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $4.15, with a high estimate of $5.86 and a low estimate of $2.85. The average target implies upside of 645.1% from the current price of $0.557.
The spread between the highest and lowest targets is 105.6%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ONCY.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 50% |
| Buy | 2 | 33% |
| Hold | 1 | 17% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.85 | +411.67% |
| Average target | $4.15 | +645.06% |
| High target | $5.86 | +952.06% |